Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate
Shots:
- Mylan has recalled two lots of Levoleucovorin (250mg/25ml) injection to the consumer level having a lot number APB032 & APB033 due to presence of foreign particle as copper salt discovered during a 12-month stability testing
- The voluntary recall is done for the lots of Levoleucovorin- distributed between August 2017 to July 2018 in the US and is conducted within the knowledge of the US FDA
- Levoleucovorin (250mg/25ml) is a single-use vial antidote for dihydrofolate reductase by methotrexate and used as a combination therapy with 5-fluorouracil for advanced metastatic colorectal cancer- developed by Alidac Pharmaceuticals
Ref: Mylan | Image: Daily Post India
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com